Fig. 1: Association of NPM1 and/or FLT3-ITD measurable residual disease (MRD) and clinical outcomes in patients with acute myeloid leukemia (AML) prior to allogeneic hematopoietic cell transplant.
From: Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia
Cumulative incidence of relapse (left) and overall survival (OS, right) are shown for patients based on the presence (MRDpos) or absence (MRDneg) of NPM1 and/or FLT3-ITD variants detected by the Invivoscribe MRD next generation sequencing assays. a All patients with NPM1-mutated AML grouped by NPM1 MRD thresholds. b Patients co-mutated for NPM1 and FLT3-ITD at baseline grouped by the NPM1 MRD status versus NPM1 and/or FLT3-ITD MRD status.
